Fennec制药 FENC 深 沪
已收盘 03-27 16:00:00 美东时间
5.91
-0.600
-9.22%
华盛通- 最 高6.54
- 今 开6.46
- 成交量 20.35万股
- 最 低 5.905
- 昨 收 6.51
- 总市值 2.02亿
- 52周最高 9.92
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 4.68
- 委 比 80.70%
- 总股本 3415.35万
- 历史最高 14.986
- 量 比 0.42
- 振 幅 9.75%
- 历史最低 3.255
- 每 手 1
- 风险率 1.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Fennec Pharmaceuticals Signals Costly Push Toward Growth
Fennec Pharmaceuticals (($TSE:FRX)) has held its Q4 earnings call. Read on for ...
03-28 08:23
Earnings Scheduled For March 24, 2026
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
Fennec Pharmaceuticals Q4 EPS $(0.17) Misses $0.04 Estimate, Sales $13.777M Miss $13.993M Estimate
Fennec Pharmaceuticals (TSX:FRX) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $0.04 by 572.22 percent. This is a 183.33 percent decrease over losses of $(0.06) per share
03-24 19:04
Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and revenue of $14.73 million. Stock gained 1.8% on Monday.
03-24 04:40
Fennec Pharmaceuticals Settles PEDMARK Patent Litigation With Cipla; Blocking Generic Entry Until September 2033
Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them
03-16 20:13
Fennec Pharma Backs Real-World Study Of PEDMARK To Protect Hearing In Cancer Patients
Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that the Tampa General Hospital (TGH) Cancer Institute is initiating a study evaluating the real-world clinical
03-04 20:09
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
Fennec Pharmaceuticals Inc. announced that Tampa General Hospital (TGH) Cancer Institute is initiating a study to evaluate the real-world clinical utility of sodium thiosulfate injection (PEDMARK®) in reducing the risk of ototoxicity in Adolescent and Young Adult (AYA) and adult cancer patients receiving cisplatin-based treatment. PEDMARK® is currently approved for pediatric patients one month of age and older with localized non-metastatic solid ...
03-04 12:05
Fennec Pharmaceuticals reports real-world data supporting PEDMARK use after cisplatin in adult head and neck cancer patients
Fennec Pharmaceuticals reports real-world data supporting PEDMARK use after cisplatin in adult head and neck cancer patients Fennec Pharmaceuticals Inc. announced new real-world data on PEDMARK (sodium thiosulfate injection) use in adults with head and neck cancers from a multi-institutional retrosp
02-20 20:03
Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
Study highlights that PEDMARK® (sodium thiosulfate injection) can be safely administered ≥6 hours after cisplatin in adults with head and neck cancers (HNC), without compromising cisplatin's antitumor activity. Most high-risk patients experienced no measurable hearing loss during or after treatment, suggesting PEDMARK®'s potential to address cisplatin-induced hearing loss, a significant survivorship issue. The study supports broader clinical adop...
02-20 12:03
